Bristol-Myers Squibb Co (BMY)
49.14
+0.21
(+0.43%)
USD |
NYSE |
Apr 22, 16:00
49.55
+0.41
(+0.83%)
Pre-Market: 05:18
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 99.37B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -27.29% |
| Valuation | |
| PE Ratio | 12.73 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 2.269 |
| Price to Book Value | 3.376 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.60 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 1.351 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 39.24% |
Profile
| Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group. |
| URL | https://www.bms.com |
| Investor Relations URL | https://www.bms.com/investors.html |
| HQ State/Province | New Jersey |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Large Cap/Value |
| Next Earnings Release | Apr. 25, 2024 |
| Last Earnings Release | Feb. 02, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Apr. 04, 2024 |
Ratings
Profile
| Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group. |
| URL | https://www.bms.com |
| Investor Relations URL | https://www.bms.com/investors.html |
| HQ State/Province | New Jersey |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Large Cap/Value |
| Next Earnings Release | Apr. 25, 2024 |
| Last Earnings Release | Feb. 02, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Apr. 04, 2024 |